Cargando…
Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress
BACKGROUND: DNA mismatch repair deficiency is present in a significant proportion of a number of solid tumours and is associated with distinct clinical behaviour. METHODS: To identify the therapeutic agents that might show selectivity for mismatch repair-deficient tumour cells, we screened a pair of...
Autores principales: | Hewish, M, Martin, S A, Elliott, R, Cunningham, D, Lord, C J, Ashworth, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590674/ https://www.ncbi.nlm.nih.gov/pubmed/23361057 http://dx.doi.org/10.1038/bjc.2013.3 |
Ejemplares similares
-
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours
por: von Bueren, A O, et al.
Publicado: (2012) -
Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma
por: Andachi, H, et al.
Publicado: (2002) -
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
por: Martin, Sarah A, et al.
Publicado: (2009) -
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer
por: Pal, T, et al.
Publicado: (2012) -
The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor α
por: Wada-Hiraike, O, et al.
Publicado: (2005)